02667 同仁堂醫養
TONGRENTANGCARE
TONGRENTANGCARE
| Register Close | 2026/07/02 IPO Closing in 4 Days |
| Listing Date | 2026/07/07 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Beijing Tong Ren Tang Healthcare Investment Co. is a subsidiary of TRT which strategically focuses on TCM healthcare services in China, delivering comprehensive TCM healthcare services to individual customers, standardized management services to business customers, and a wide selection of healthcare products and other products.
--
As of June 17, 2026, the Group had established tiered TCM healthcare service network comprising 13 self-owned offline medical institutions and an Internet hospital, as well as 13 managed offline medical institutions. Benefit from the well-established brand “Tong Ren Tang” and quality pharmaceuticals, the Group has accumulated and integrated abundant offline and online healthcare resources.
--
The Group is the largest TCM hospital group in the non-public TCM hospital healthcare service industry in China in 2025 in terms of the total number of out-patient and in-patient visits, with a market share of 1.5%. In terms of the total TCM healthcare service revenue in 2025, the Group ranked second with a market share of 0.2% in the non-public TCM hospital healthcare service industry, the market size of which represented 54.9% of the total market size of the TCM healthcare service industry in China in the same year.
--
The Group generated revenue primarily from TCM healthcare services; management services; and sale of healthcare products and other products, its customers primarily consist of individual customers that receive TCM healthcare services at offline medical institutions or Internet hospital owned and operated by it; individual customers that purchase healthcare products or other products at its offline standalone stores; and retailers that procure Angong Niuhuang Pills series from it; and medical institutions and business customers that receive its management services.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 500 |
GLOBAL OFFERING
| No. of Offer Shares | 108.15M H shares |
| No. of International Offer Shares | 97.34M H shares |
| No. of HK Offer Shares | 10.82M H shares |
| Offer Price | $5.48 - $6.21 |
| Stock Code | 2667 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, ICBC International Securities Limited, GF Securities (Hong Kong) Brokerage Limited, ABCI Securities Company Limited, West Bull Securities Limited, Patrons Securities Limited, Futu Securities International (Hong Kong) Limited, Livermore Holdings Limited, Tiger Brokers (HK) Global Limited |
TIME TABLE
| Application Period | Jun 26 (Fri) - noon, Jul 02 (Thu) |
| Price Determination Date | Jul 03 (Fri) |
| Result Announcement Date | On or before Jul 06 (Mon) |
| Result Announcement Date | On or before Jul 06 (Mon) |
| Result Announcement Date | On or before Jul 07 (Tue) |
| Dealings in Shares commence on | Jul 07, 2026. (Tue) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $5.48 - $6.21 |
| Capitalization | 2.55B - 2.89B |
| NAV / share ($) | $1.78 - $1.94 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 5.85, the net proceeds raised would be HKD 562.40M, of which |
| 63.7% : expansion of TCM healthcare service network |
| 26.3% : repayment of certain of outstanding bank loans |
| 10% : working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).